{"product_id":"inab-vrio-analysis","title":"IN8bio, Inc. (INAB): VRIO Analysis [Mar-2026 Updated]","description":"\u003cbr\u003e\u003cp\u003eIs IN8bio, Inc. (INAB) truly built for lasting success? This VRIO analysis rigorously tests the core of their business - its Value, Rarity, Inimitability, and Organization - to uncover whether they possess a sustainable competitive advantage. Dive in now to see the definitive verdict on what truly sets IN8bio, Inc. (INAB) apart from the competition and where their future strength lies.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eIN8bio, Inc. (INAB) - VRIO Analysis: \u003cstrong\u003e1. Proprietary DeltEx™ Allo Manufacturing Platform\u003c\/strong\u003e\n\u003c\/h2\u003e\n\u003cp\u003eYou’re looking at the engine room of IN8bio, Inc. (INAB), and frankly, it’s where the value is being built. This DeltEx™ platform is what turns a promising cell type - gamma-delta T cells - into a commercial reality. The key takeaway here is that their process has already earned industry validation, but the clock is ticking to translate that process win into a definitive clinical win.\u003c\/p\u003e\n\n\u003ch3\u003eValue: Scalable, Consistent Allogeneic Production\u003c\/h3\u003e\n\u003cp\u003eThe Value of the DeltEx™ Allo Manufacturing Platform is its ability to deliver consistent, off-the-shelf (allogeneic) gamma-delta ($\\gamma\\delta$) T cells. This consistency is non-negotiable for commercial success, as it drastically cuts down on patient-specific lead times compared to older methods. The platform’s success is evidenced by its ability to consistently reprogram donor T cells to express $\\gamma\\delta$ T cell receptors (TCRs) across all clinical batches, independent of the starting donor material. This manufacturing rigor is what underpinned the durable results seen in the INB-100 trial, where the initial cohort achieved \u003cstrong\u003e100%\u003c\/strong\u003e relapse-free survival over one year.\u003c\/p\u003e\n\n\u003ch3\u003eRarity: Industry Recognition and Technical Lead\u003c\/h3\u003e\n\u003cp\u003eThe Rarity factor is high because IN8bio, Inc. secured the Host Region USA East Abstract Award at the International Society for Cell \u0026amp; Gene Therapy (ISCT) 2025 Annual Meeting for this very platform. This award signals a recognized technical lead in generating consistent, activated, and primed $\\gamma\\delta$ products, which many competitors in this emerging space struggle with. The platform’s ability to generate uniform potency markers across different donors is defintely rare in allogeneic cell therapy right now.\u003c\/p\u003e\n\n\u003ch3\u003eImitability: Proprietary Know-How and Analytics\u003c\/h3\u003e\n\u003cp\u003eImitability is moderate to high. While $\\gamma\\delta$ T cells are a known entity, the specific, proprietary process details - including the deep analytics and genomics used for characterization - are protected as trade secrets. Replicating the exact process that yields the observed clinical durability and TCR reprogramming consistency would require significant reverse engineering and process development investment from a competitor. It’s not just the recipe; it’s the precise execution.\u003c\/p\u003e\n\n\u003ch3\u003eOrganization: Operational Focus and Resource Allocation\u003c\/h3\u003e\n\u003cp\u003eOrganizationally, IN8bio, Inc. shows strong commitment by automating this process for rapid, reproducible production and maintaining hands-on control. As of the third quarter ended September 30, 2025, the company reported a net loss of $\u003cstrong\u003e3.9 million\u003c\/strong\u003e and held cash of $\u003cstrong\u003e10.7 million\u003c\/strong\u003e. This financial reality means the organization must be laser-focused on leveraging this platform to generate pivotal data quickly. They are actively expanding clinical operations for INB-100 to accelerate enrollment, showing organizational alignment with the platform’s clinical validation.\u003c\/p\u003e\n\u003cp\u003eHere’s the quick math on organizational focus:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eExpand INB-100 enrollment sites now.\u003c\/li\u003e\n\u003cli\u003eMaintain strict control over process IP.\u003c\/li\u003e\n\u003cli\u003ePrioritize data package generation over non-core programs.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch3\u003eCompetitive Advantage: Temporary, Data-Dependent\u003c\/h3\u003e\n\u003cp\u003eThe current Competitive Advantage is \u003cstrong\u003eTemporary\u003c\/strong\u003e. The platform itself is a strong asset, but in cell therapy, process superiority erodes fast without corresponding clinical proof. The advantage lasts only as long as IN8bio, Inc. can secure pivotal data demonstrating superior patient outcomes (like the \u003cstrong\u003e16.1 months\u003c\/strong\u003e mPFS for INB-200 in GBM patients as of May 31, 2025) before a competitor leapfrogs their manufacturing technology.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eVRIO Dimension\u003c\/td\u003e\n\u003ctd\u003eAssessment\u003c\/td\u003e\n\u003ctd\u003eKey Supporting Data\/Fact\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eValue\u003c\/td\u003e\n\u003ctd\u003eYes\u003c\/td\u003e\n\u003ctd\u003eEnables consistent, off-the-shelf $\\gamma\\delta$ T cell production.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRarity\u003c\/td\u003e\n\u003ctd\u003eYes\u003c\/td\u003e\n\u003ctd\u003eReceived ISCT 2025 Host Region Abstract Award.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eImitability\u003c\/td\u003e\n\u003ctd\u003eModerate\/High\u003c\/td\u003e\n\u003ctd\u003eProprietary deep analytics and genomics protect the process.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOrganization\u003c\/td\u003e\n\u003ctd\u003eYes\u003c\/td\u003e\n\u003ctd\u003eAutomated for rapid production; expanding clinical sites as of Q3 2025.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCompetitive Advantage\u003c\/td\u003e\n\u003ctd\u003eTemporary\u003c\/td\u003e\n\u003ctd\u003eRequires rapid translation of platform strength into superior, durable clinical data.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eFinance: draft 13-week cash view by Friday.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eIN8bio, Inc. (INAB) - VRIO Analysis: \u003cstrong\u003e2. INB-100 Clinical Durability in AML\u003c\/strong\u003e\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue: Provides compelling, differentiated clinical evidence for a high-unmet-need indication (post-transplant Acute Myeloid Leukemia, AML), potentially de-risking the registrational pathway.\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity: High. Reporting that \u003cstrong\u003e100%\u003c\/strong\u003e of initial AML patients treated with INB-100 remained relapse-free after a median follow-up exceeding 19.7 months is a standout result in this field.\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe latest reported data indicates that 100% of AML patients treated with INB-100 remain relapse-free as of the February 2025 data presentation, with a median follow-up exceeding 20.1 months across all treated AML patients (N=9). The original cohort of AML patients reached a median Complete Remission (CR) of 23.3 months.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eMetric\u003c\/td\u003e\n\u003ctd\u003eINB-100 AML Patients (Reported Data)\u003c\/td\u003e\n\u003ctd\u003eHistorical AML Post-HSCT Controls\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003e1-Year Progression-Free Survival (PFS)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e100%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eApproximately 40-50% expected PFS rate\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e1-Year Overall Survival (OS)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e100%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eImplied lower than 100%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRelapse Rate (by One-Year)\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e0%\u003c\/strong\u003e (No relapses observed)\u003c\/td\u003e\n\u003ctd\u003eUp to nearly 50% relapse by one-year\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMedian Follow-up (Latest Data Cut)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e20.1 months\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003e\u003cstrong\u003eImitability: Low. Competitors cannot easily imitate this because it requires years of patient follow-up and successful execution of their specific clinical protocol.\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eEvidence of \u003cstrong\u003ein vivo\u003c\/strong\u003e expansion and long-term persistence of the allogeneic gamma-delta T cells has been observed through 1 year following a single administration, a first for an allogeneic cellular therapy product.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization: Strong. The company has prioritized cash resources to focus on driving this key program to the next milestone, showing clear strategic alignment.\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eThe company implemented a pipeline prioritization in September 2024, suspending enrollment in the Phase 2 clinical trial of INB-400 for glioblastoma to focus on INB-100.\u003c\/li\u003e\n\u003cli\u003eA workforce reduction of approximately 49% was implemented in Q3 2024 to optimize resource allocation and preserve cash.\u003c\/li\u003e\n\u003cli\u003eAs of September 30, 2024, cash was $4.0 million, which was supplemented by a $11.6 million net proceeds Private Placement closed in October 2024.\u003c\/li\u003e\n\u003cli\u003eThe company received FDA guidance on the registrational path for INB-100 in AML via a Type B meeting.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage: Sustained. This level of durable, positive clinical data creates a significant lead in credibility and regulatory momentum that is hard for others to catch up to.\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe 100% one-year PFS and OS rates in AML patients treated with INB-100 significantly exceed historical control data for patients undergoing hematopoietic stem cell transplantation (HSCT).\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eIN8bio, Inc. (INAB) - VRIO Analysis: \u003cstrong\u003e3. DeltEx™ Platform Versatility (Allogeneic \u0026amp; Autologous)\u003c\/strong\u003e\n\u003c\/h2\u003e\n\u003cp\u003eThe DeltEx™ platform's ability to support both allogeneic and autologous cell therapy manufacturing under one technological suite is a key component of its resource allocation strategy.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eValue: Allows IN8bio, Inc. to address multiple indications (AML, Glioblastoma\/GBM) using both allogeneic (off-the-shelf) and autologous (patient-specific) approaches, maximizing the platform's return on investment.\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eThe platform supports \u003cstrong\u003eINB-100\u003c\/strong\u003e, an allogeneic $\\gamma\\delta$ T cell therapy for Acute Myeloid Leukemia (AML) as a post-transplant maintenance therapy.\u003c\/li\u003e\n\u003cli\u003eThe platform supports \u003cstrong\u003eINB-200\u003c\/strong\u003e (Phase 1) and \u003cstrong\u003eINB-400\u003c\/strong\u003e (Phase 2), autologous DeltEx DRI $\\gamma\\delta$ T cells for Glioblastoma (GBM).\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eClinical performance data supporting the platform's value:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eProgram\u003c\/th\u003e\n\u003cth\u003eIndication\u003c\/th\u003e\n\u003cth\u003eKey Metric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003cth\u003eAs of Date\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eINB-100\u003c\/td\u003e\n\u003ctd\u003eAML\u003c\/td\u003e\n\u003ctd\u003eComplete Remission (CR) Rate\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e100%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eAugust 1, 2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eINB-100\u003c\/td\u003e\n\u003ctd\u003eAML\u003c\/td\u003e\n\u003ctd\u003eMedian CR (Original Cohort)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e23.3 months\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eJanuary 17, 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eINB-100\u003c\/td\u003e\n\u003ctd\u003eAML\u003c\/td\u003e\n\u003ctd\u003eMedian Duration Across All Treated Patients (N=9)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e20.1 months\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eFebruary 11, 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eINB-200\u003c\/td\u003e\n\u003ctd\u003eGBM\u003c\/td\u003e\n\u003ctd\u003eMedian Progression-Free Survival (mPFS)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e16.1 months\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eMay 31, 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eINB-200\u003c\/td\u003e\n\u003ctd\u003eGBM\u003c\/td\u003e\n\u003ctd\u003eHistorical Standard-of-Care mPFS\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e6.9 months\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eMay 31, 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eINB-200\u003c\/td\u003e\n\u003ctd\u003eGBM\u003c\/td\u003e\n\u003ctd\u003ePatients in PFS (Multiple Doses)\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e40%\u003c\/strong\u003e (over 18 months)\u003c\/td\u003e\n\u003ctd\u003eMay 31, 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eINB-200\u003c\/td\u003e\n\u003ctd\u003eGBM\u003c\/td\u003e\n\u003ctd\u003eLongest Patient Progression-Free Duration\u003c\/td\u003e\n\u003ctd\u003eOver \u003cstrong\u003efour years\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eAugust 7, 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003e\u003cstrong\u003eRarity: Moderate. While many companies focus on one or the other, having proven capability across both modalities under one platform is less common.\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe DeltEx platform employs allogeneic, autologous, and genetically modified approaches to develop cell therapies.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eImitability: Moderate. The core $\\gamma\\delta$ T cell biology is shared, but adapting the manufacturing and genetic engineering for both autologous (INB-200\/400) and allogeneic (INB-100) use requires distinct process know-how.\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eThe DeltEx™ platform received the Host Region USA East Abstract Award at the ISCT \u003cstrong\u003e2025\u003c\/strong\u003e Annual Meeting for its robust manufacturing processes.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eOrganization: Moderate. While the focus is on INB-100, the organization still monitors the GBM assets (INB-200\/400) and explores partnerships for the solid tumor program.\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eThe Phase 2 trial for \u003cstrong\u003eINB-400\u003c\/strong\u003e was suspended in September \u003cstrong\u003e2024\u003c\/strong\u003e due to resource allocation.\u003c\/li\u003e\n\u003cli\u003eThe organization announced a workforce reduction of approximately \u003cstrong\u003e49%\u003c\/strong\u003e in September \u003cstrong\u003e2024\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eResearch and Development (R\u0026amp;D) expenses were \u003cstrong\u003e$2.5 million\u003c\/strong\u003e for the three months ended June 30, \u003cstrong\u003e2025\u003c\/strong\u003e, compared with \u003cstrong\u003e$5.2 million\u003c\/strong\u003e in the prior year period.\u003c\/li\u003e\n\u003cli\u003eCash on hand as of June 30, \u003cstrong\u003e2025\u003c\/strong\u003e was \u003cstrong\u003e$13.2 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eThe company extended its runway into June \u003cstrong\u003e2026\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage: Temporary. The versatility is valuable now, but if the GBM trials remain on hold or partnership talks stall, the value of the suspended programs will erode.\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe suspension of the \u003cstrong\u003eINB-400\u003c\/strong\u003e Phase 2 trial occurred in September \u003cstrong\u003e2024\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eIN8bio, Inc. (INAB) - VRIO Analysis: \u003cstrong\u003e4. Foundational Intellectual Property (IP) Portfolio\u003c\/strong\u003e\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue\u003c\/strong\u003e: Protects core technology, including the DeltEx DRI platform, and creates a barrier to entry by covering synergistic combinations with CAR-T and Checkpoint Inhibitors (CPIs). The company announced newly granted global patents covering these combinations on September 19, 2023. As of that date, IN8bio held 19 total granted U.S. and international patents, alongside numerous pending applications.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity\u003c\/strong\u003e: Moderate. Many biotechs have IP, but patents specifically covering the use of genetically modified $\\gamma\\delta$ T cells resistant to chemotherapy are a specific, valuable niche. An example is the European patent (EP3552617) issued on July 21, 2022, which broadened coverage to include Natural Killer (NK) cells with the Drug Resistant Immunotherapy (DRI) platform.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability\u003c\/strong\u003e: Low. Granted patents are legally protected assets that competitors cannot easily circumvent without infringing on IN8bio, Inc.'s rights. The commitment to developing and protecting this technology is reflected in the company's financial outlays.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization\u003c\/strong\u003e: Strong. The company actively pursued and secured these global patents, showing a proactive approach to establishing a defensible market position. The IP is co-owned by and exclusively licensed to IN8bio from the University of Alabama at Birmingham (UAB), Children's Healthcare of Atlanta (CHOA), and Emory University (Emory).\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage\u003c\/strong\u003e: Sustained. Patents provide a legal moat, offering the longest-lasting protection against direct imitation, assuming they are broad enough. The company's investment in this area is demonstrated by its financial reporting.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Granted Patents (U.S. \u0026amp; International)\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e19\u003c\/strong\u003e (As of September 2023)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eResearch and Development (R\u0026amp;D) Expenses (Year Ended Dec 31, 2024)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$17.2 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D Expenses (Year Ended Dec 31, 2023)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$16.8 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet Loss (Year Ended Dec 31, 2024)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$30.7 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash Position (As of Dec 31, 2024)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$11.1 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eThe company's portfolio includes specific patents covering the DRI platform's application across different innate immune cell types.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eThe DeltEx DRI platform covers genetic modification conveying chemotherapy resistance in gamma-delta T cells and Natural Killer (NK) cells.\u003c\/li\u003e\n\u003cli\u003eNewly granted patents specifically expanded coverage to encompass synergistic use with CAR-T and CPIs.\u003c\/li\u003e\n\u003cli\u003eThe European patent EP3552617 covers the DRI-based approach for cell engineering.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eIN8bio, Inc. (INAB) - VRIO Analysis: \u003cstrong\u003e5. DeltEx DRI Technology (Chemotherapy Resistance)\u003c\/strong\u003e\n\u003c\/h2\u003e\n\u003cp\u003eThe DeltEx Drug Resistant Immunotherapy (DRI) platform is central to IN8bio's pipeline, specifically engineered to allow \u003cstrong\u003e$\\gamma\\delta$ T cells\u003c\/strong\u003e to survive standard-of-care chemotherapy regimens. This is the basis for programs like INB-200 and INB-400 in Glioblastoma (GBM) and INB-100 in AML.\u003c\/p\u003e\n\n\u003ch3\u003eValue\u003c\/h3\u003e\n\u003cp\u003eThe intrinsic resistance mechanism allows for synergistic dosing with chemotherapy, aiming to eliminate residual, chemotherapy-resistant cancer cells. Clinical data from the INB-200\/INB-400 GBM trials demonstrate this potential value:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eMedian Progression-Free Survival (mPFS) for DeltEx DRI treated patients: \u003cstrong\u003e13.0 months\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eMedian Overall Survival (mOS) for DeltEx DRI treated patients (repeated doses): \u003cstrong\u003e16.4+ months\u003c\/strong\u003e (as of October 31, 2025).\u003c\/li\u003e\n\u003cli\u003eFor INB-100 in AML, \u003cstrong\u003e100%\u003c\/strong\u003e of treated patients remain in complete remission (CR) as of the 2024 European Hematology Association Congress.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch3\u003eRarity\u003c\/h3\u003e\n\u003cp\u003eThe capability to genetically engineer T cells for intrinsic resistance to common conditioning regimens is a sophisticated and rare feature in the current cellular therapy landscape. The INB-200 trial was the first genetically engineered \u003cstrong\u003e$\\gamma\\delta$ T cell therapy\u003c\/strong\u003e administered to patients.\u003c\/p\u003e\n\n\u003ch3\u003eImitability\u003c\/h3\u003e\n\u003cp\u003eReplicating this technology requires reverse-engineering the specific intracellular genetic construct used to confer drug resistance, a high technical hurdle. The technology is integrated into the DeltEx™ platform, which also includes advanced manufacturing expertise for \u003cstrong\u003eex-vivo, expanded, activated $\\gamma\\delta$ T cells\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003ch3\u003eOrganization\u003c\/h3\u003e\n\u003cp\u003eThe technology is deeply integrated into the company's platform, suggesting strong internal expertise in \u003cstrong\u003e$\\gamma\\delta$ T cell genetic engineering\u003c\/strong\u003e and scalable manufacturing. The company secured net proceeds of \u003cstrong\u003e$11.6 million\u003c\/strong\u003e in October 2024 to continue advancing development, providing a cash runway into the first quarter of 2026.\u003c\/p\u003e\n\n\u003ch3\u003eCompetitive Advantage\u003c\/h3\u003e\n\u003cp\u003eIf the combination approach proves superior in clinical settings, the DRI mechanism provides a sustained technological differentiator. The comparative efficacy data from the GBM trials highlights this potential advantage:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eMetric\u003c\/td\u003e\n\u003ctd\u003eDeltEx DRI Treated Patients (n=17 total, 14 repeated doses)\u003c\/td\u003e\n\u003ctd\u003eStandard-of-Care (SoC) Control Group\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eMedian Progression-Free Survival (mPFS)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e13.0 months\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e6.6 months\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMedian Overall Survival (mOS)\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e16.4+ months\u003c\/strong\u003e (Not Reached)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e11.0 months\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eFurther supporting durability, \u003cstrong\u003e40%\u003c\/strong\u003e of patients receiving multiple doses in the INB-200 trial remained progression-free for over \u003cstrong\u003e18 months\u003c\/strong\u003e as of May 31, 2025.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eIN8bio, Inc. (INAB) - VRIO Analysis: \u003cstrong\u003e6. INB-200 Clinical Efficacy in Glioblastoma (GBM)\u003c\/strong\u003e\n\u003c\/h2\u003e\n\u003ch3\u003eValue\u003c\/h3\u003e\n\u003cp\u003eDemonstrates significant improvement over historical benchmarks in a notoriously difficult-to-treat solid tumor indication, validating the platform’s potential beyond hematologic cancers.\u003c\/p\u003e\n\n\u003ch3\u003eRarity\u003c\/h3\u003e\n\u003cp\u003eModerate. Achieving a median Progression-Free Survival (mPFS) of \u003cstrong\u003e16.1 months\u003c\/strong\u003e, more than double the standard \u003cstrong\u003e6.9 months\u003c\/strong\u003e for GBM patients receiving multiple doses, is rare.\u003c\/p\u003e\n\n\u003ch3\u003eImitability\u003c\/h3\u003e\n\u003cp\u003eLow. This is based on executed clinical trials; competitors must replicate the entire complex trial process to claim parity. The Phase 1 trial enrolled \u003cstrong\u003e23 patients\u003c\/strong\u003e, with \u003cstrong\u003e11 dosed\u003c\/strong\u003e at one reporting point.\u003c\/p\u003e\n\n\u003ch3\u003eOrganization\u003c\/h3\u003e\n\u003cp\u003eModerate. While enrollment is suspended, the organization continues to monitor patients and plans to report long-term data, showing commitment to data generation. The Phase 1 study was \u003cstrong\u003efully enrolled\u003c\/strong\u003e. A patient in the INB-200 clinical trial surpassed \u003cstrong\u003efour years\u003c\/strong\u003e without progression.\u003c\/p\u003e\n\n\u003ch3\u003eCompetitive Advantage\u003c\/h3\u003e\n\u003cp\u003eTemporary. The advantage is tied to the data; if the GBM program is not advanced soon, the lead over standard-of-care could be lost as new standards emerge. Historically, an improvement of just \u003cstrong\u003e2 to 3 months\u003c\/strong\u003e in mPFS has been considered clinically significant and the bar for FDA approval.\u003c\/p\u003e\n\n\u003cp\u003eThe efficacy data relative to historical Standard of Care (SOC) benchmarks are summarized below:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eMetric\u003c\/td\u003e\n\u003ctd\u003eINB-200 (Multiple Doses)\u003c\/td\u003e\n\u003ctd\u003eHistorical SOC (Stupp Protocol)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eMedian Progression-Free Survival (mPFS)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e16.1 months\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e6.9 months\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003emPFS Improvement Percentage\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e+132.6%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHistorical Median Overall Survival (mOS)\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e14.6 months\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eFurther details on the clinical observations include:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003e40%\u003c\/strong\u003e of patients who received repeated doses of INB-200 remained alive and progression-free for a median of over \u003cstrong\u003etwo years\u003c\/strong\u003e as of May 31, 2025.\u003c\/li\u003e\n\u003cli\u003eThe mPFS of \u003cstrong\u003e16.1 months\u003c\/strong\u003e has already surpassed the historical median Overall Survival (mOS) of \u003cstrong\u003e14.6 months\u003c\/strong\u003e associated with the SOC Stupp protocol alone.\u003c\/li\u003e\n\u003cli\u003eNo dose-limiting toxicities (DLTs), Cytokine Release Syndrome (CRS), or neurotoxicity (ICANS) were observed among the \u003cstrong\u003e13\u003c\/strong\u003e patients treated with INB-200.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eIN8bio, Inc. (INAB) - VRIO Analysis: \u003cstrong\u003e7. Novel Gamma-Delta T Cell Engager (INB-619)\u003c\/strong\u003e\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Extends the platform into a new modality (T cell engager) with potential applications in both oncology and autoimmune diseases, like lupus, broadening the total addressable market.\u003c\/p\u003e\n\u003cp\u003ePreclinical data in systemic lupus erythematosus (SLE) donor models demonstrated \u003cstrong\u003ecomplete elimination of B cells\u003c\/strong\u003e with efficacy equivalent to approved CD19 and CD20 engagers, including blinatumomab and mosunetuzumab. INB-619 is a CD19-targeted, pan-$\\gamma\\delta$ T cell engager designed to activate and expand both V-delta-1 (V$\\delta$1+) and V-delta-2 (V$\\delta$2+) subsets.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eINB-619 (Preclinical Data)\u003c\/th\u003e\n\u003cth\u003eConventional CD3-Engagers (Context)\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eB Cell Depletion (SLE Models)\u003c\/td\u003e\n\u003ctd\u003eComplete elimination\u003c\/td\u003e\n\u003ctd\u003eEquivalent efficacy to marketed agents\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAdverse Cytokine Release (e.g., IL-6)\u003c\/td\u003e\n\u003ctd\u003eMinimal or no detectable release\u003c\/td\u003e\n\u003ctd\u003eAssociated with CRS risk\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eT Cell Activation Target\u003c\/td\u003e\n\u003ctd\u003eSelective $\\gamma\\delta$ T cell receptor ($\\gamma\\delta$-TCR)\u003c\/td\u003e\n\u003ctd\u003eCD3 receptor engagement\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e$\\gamma\\delta$ T Cell Expansion\u003c\/td\u003e\n\u003ctd\u003eRobust expansion of V$\\delta$1+ and V$\\delta$2+ subsets\u003c\/td\u003e\n\u003ctd\u003eLimited by low baseline $\\gamma\\delta$ T cell counts\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCytotoxicity EC50\u003c\/td\u003e\n\u003ctd\u003e26 to 51 pM for $\\gamma\\delta$ T cell activation\u003c\/td\u003e\n\u003ctd\u003eNot directly comparable\/Different mechanism\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Moderate. Developing a $\\gamma\\delta$ T cell engager, rather than the more common $\\alpha\\beta$ CAR-T or CD3-based engagers, represents a novel approach to mobilizing the immune system.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eINB-619 uniquely targets through the $\\gamma\\delta$-TCR and does not require CD3 engagement.\u003c\/li\u003e\n\u003cli\u003eIt selectively expanded $\\gamma\\delta$ T cells from both SLE and healthy donors without activating CD4+ or CD8+ $\\alpha\\beta$ T cells.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Moderate. The preclinical data showing deep B cell depletion for lupus is promising, but the technology is still early-stage compared to the clinical assets.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eThe technology is fully developed in-house.\u003c\/li\u003e\n\u003cli\u003ePreclinical data was presented at the 2025 American College of Rheumatology (ACR) Convergence Meeting.\u003c\/li\u003e\n\u003cli\u003eThe potential for improved safety profile is based on minimal cytokine release compared to conventional TCEs.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e Moderate. Preclinical data was presented in late 2025, showing the R\u0026amp;D engine is active, but resources are clearly tilted toward INB-100.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eAdditional preclinical data was scheduled for presentation at the ASH Annual Meeting, December 6-9, 2025.\u003c\/li\u003e\n\u003cli\u003eResearch and Development (R\u0026amp;D) expenses for the three months ended September 30, 2025, were $2.1 million.\u003c\/li\u003e\n\u003cli\u003eCash on hand as of September 30, 2025, was $10.7 million.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Temporary. It’s an emerging opportunity; the advantage is in being an early mover with this specific $\\gamma\\delta$ T cell engager approach.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eThe design aims to allow for higher doses, deeper B cell depletion and immune reset not observed with other protein engagers to date.\u003c\/li\u003e\n\u003cli\u003eIt addresses the challenge of low baseline $\\gamma\\delta$ T cell counts that have limited earlier $\\gamma\\delta$-TCE technologies.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eIN8bio, Inc. (INAB) - VRIO Analysis: \u003cstrong\u003e8. Demonstrated In Vivo Persistence and Expansion\u003c\/strong\u003e\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eCells demonstrate durable in vivo expansion and persistence up to \u003cstrong\u003e365 days\u003c\/strong\u003e following a single administration of INB-100. This persistence suggests continued surveillance against residual leukemic cells.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003ePersistence and expansion observed up to \u003cstrong\u003e365 days\u003c\/strong\u003e post-treatment is noted as the \u003cstrong\u003efirst-ever\u003c\/strong\u003e for an allogeneic cellular therapy.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003e100%\u003c\/strong\u003e of patients ($\\text{n}=10$) surpassed \u003cstrong\u003eone-year\u003c\/strong\u003e survival as of September 30, 2024.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e100%\u003c\/strong\u003e of evaluable leukemia patients ($\\text{n}=10\/10$) achieved durable Complete Remission (CR) at \u003cstrong\u003e1-year\u003c\/strong\u003e as of May 31, 2024.\u003c\/li\u003e\n\u003cli\u003eTwo patients remain alive and relapse-free for over \u003cstrong\u003ethree and a half years\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003eImitability\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eBiological outcome of specific cell engineering and expansion process. The DeltEx™ Allo manufacturing process demonstrated consistent production.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eOutcome validates the core hypothesis of the DeltEx platform.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003e100%\u003c\/strong\u003e of initial cohort patients remained relapse-free for over \u003cstrong\u003eone year\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eMedian CR across all treated AML patients ($\\text{N}=9$) is \u003cstrong\u003e20.1 months\u003c\/strong\u003e (as of January 17, 2025).\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eSustained biological advantage proven by long-term persistence in an allogeneic setting.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eMetric\u003c\/td\u003e\n\u003ctd\u003eINB-100 (AML Patients)\u003c\/td\u003e\n\u003ctd\u003eHistorical Control (CIBMTR)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003e1-Year Progression-Free Survival (PFS)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e100%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e67.8%\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e1-Year Overall Survival (OS)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e100%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e74.7%\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cbr\u003e\u003ch2\u003eIN8bio, Inc. (INAB) - VRIO Analysis: \u003cstrong\u003e9. Focused Clinical Strategy and Management Visibility\u003c\/strong\u003e\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Clear prioritization of the INB-100 AML program conserves cash, while CEO William Ho’s active participation in major conferences (like IO360° 2025) maintains investor and KOL engagement.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Moderate. Many small biotechs struggle with focus; IN8bio, Inc.'s decision to suspend GBM enrollment to fund AML is a clear, albeit tough, strategic move.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Low. This is a function of leadership decisions and capital allocation, which is unique to the current management team and financial runway.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e Strong. The executive team is clearly communicating strategic shifts and presenting data at key scientific meetings, which is vital for maintaining credibility and future financing optionality.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Temporary. This advantage relies on the current management team and financial discipline; a change in leadership or a sudden cash crunch could quickly undermine this focus.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eClinical and Financial Metrics Supporting Strategy:\u003c\/strong\u003e\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eMetric\u003c\/td\u003e\n\u003ctd\u003eProgram\/Date Context\u003c\/td\u003e\n\u003ctd\u003eReported Value\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eINB-100 AML Progression-Free Survival (PFS)\u003c\/td\u003e\n\u003ctd\u003eAML Patients, as of August 30, 2024\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e100%\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMedian Follow-up\u003c\/td\u003e\n\u003ctd\u003eINB-100 AML Patients\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e18.7 months\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTarget Expansion Enrollment\u003c\/td\u003e\n\u003ctd\u003eExpected completion H1 \u003cstrong\u003e2025\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eApprox. \u003cstrong\u003e25\u003c\/strong\u003e patients\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash on Hand\u003c\/td\u003e\n\u003ctd\u003eEnd of June\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$10.2 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash \u0026amp; Cash Equivalents\u003c\/td\u003e\n\u003ctd\u003eLatest Balance Sheet Data\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$10.69 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet Cash Position\u003c\/td\u003e\n\u003ctd\u003eLatest Balance Sheet Data\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$7.73 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOperating Cash Flow (Last 12 Months)\u003c\/td\u003e\n\u003ctd\u003eLatest Income Statement Data\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e-$14.60 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eWorkforce Reduction\u003c\/td\u003e\n\u003ctd\u003eCompleted in \u003cstrong\u003e3Q24\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e49%\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eExecutive Pay Reduction\u003c\/td\u003e\n\u003ctd\u003eEffective September \u003cstrong\u003e1\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e11%\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003e\u003cstrong\u003eManagement Visibility Events:\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eCEO William Ho presented at NobleCon20 on \u003cstrong\u003eDecember 3, 2024\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eCEO William Ho presented at the TD Cowen 45th Annual Health Care Conference on \u003cstrong\u003eMarch 3, 2025\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eCEO William Ho was Co-Chairing Day 2 of the Immuno-Oncology 360° (IO360°) Conference \u003cstrong\u003e2025\u003c\/strong\u003e (March \u003cstrong\u003e24-26\u003c\/strong\u003e, \u003cstrong\u003e2025\u003c\/strong\u003e).\u003c\/li\u003e\n\u003cli\u003eThe Company received regulatory guidance from the FDA for INB-100 in \u003cstrong\u003eSummer 2024\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003ePhase 1 INB-200 trial for GBM has \u003cstrong\u003e21\u003c\/strong\u003e patients enrolled.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eFinance: Draft 13-week cash view by Friday.\u003c\/p\u003e","brand":"dcf.fm","offers":[{"title":"Default Title","offer_id":45516186845333,"sku":"inab-vrio-analysis","price":7.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0630\/5189\/0837\/files\/inab-vrio-analysis.png?v=1740184083","url":"https:\/\/dcf-analysis.com\/products\/inab-vrio-analysis","provider":"AI-Powered Discounted Cash Flow Model Templates","version":"1.0","type":"link"}